

NICE Technology Appraisals About Medicines: Formulary Adherence

Technology appraisal (TA) Titles are hyperlinks to full guidance	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE	
			Included on the Trust Formulary for this indication Yes OR No	Reason provided if "No"
2009-10				
Rheumatoid arthritis - certolizumab pegol (TA186)	28/02/2010	Certolizumab pegol – a recommended option for severe 'active' disease if methotrexate and another DMARD unsuccessful. Usually given with methotrexate, but monotherapy if methotrexate not tolerated. Use as per TA130.	Yes	
Soft tissue sarcoma - trabectedin (TA185)	28/02/2010	Trabectedin – a recommended option for advanced disease where treatment with anthracyclines and ifosfamide is unsuitable, has failed, or is not tolerated.	No	This medicine is not applicable to C&W
Lung cancer (small-cell) - topotecan (TA184)	30/11/2009	Oral topotecan – a recommended option for relapsed small-cell lung cancer in specified circumstances. IV topotecan – not recommended.	Yes	
Cervical cancer (recurrent) - topotecan (TA183)	31/10/2009	Topotecan – a recommended option for recurrent or stage IVB cervical cancer with cisplatin, if cisplatin not given before.	No	This medicine is not applicable to C&W
Acute coronary syndrome - prasugrel (TA182)	31/10/2009	Prasugrel – a recommended option with aspirin for patients undergoing PCI in specific circumstances.	Yes	
Lung cancer (non-small-cell, first line treatment) - pemetrexed (TA181)	30/09/2009	Pemetrexed – a recommended first line option for locally advanced or metastatic adeno-or large-cell carcinoma types of non-small-cell lung cancer.	Yes	
Gastrointestinal stromal tumours - sunitinib (TA179)	30/09/2009	Sunitinib – a recommended option for unresectable or metastatic malignant GIST if imatinib unsuccessful or unsuitable.	No	This medicine is not applicable to C&W
Psoriasis - ustekinumab (TA180)	30/09/2009	Ustekinumab – a recommended option for severe plaque psoriasis when other treatments unsuccessful or unsuitable.	Yes	
Colorectal cancer (first line) - cetuximab (TA176)	31/08/2009	Cetuximab – recommended in combination with FOLFOX as first line option for metastatic colorectal cancer in specific circumstances. Use with FOLFIRI, if FOLFOX unsuitable.	Yes	
Eczema (chronic) - alitretinoin (TA177)	31/08/2009	Alitretinoin – a recommended option for severe chronic hand eczema unresponsive to potent topical steroids.	Yes	

Renal cell carcinoma (TA178)	31/08/2009	Bevacizumab, sorafenib, temsirolimus – not recommended first line for advanced and/or metastatic renal cell carcinoma. Sorafenib, sunitinib – not recommended second line.	Yes	
Hepatitis B - tenofovir disoproxil fumarate (TA173)	31/07/2009	Tenofovir disoproxil – a recommended option for chronic hepatitis B.	Yes	
Leukaemia (chronic lymphocytic, first line) - rituximab (TA174)	31/07/2009	Rituximab – a recommended first line option for chronic lymphocytic leukaemia only in combination with fludarabine and cyclophosphamide.	Yes	
Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal) (TA175)	31/07/2009	Gefitinib – unable to recommend NHS use. TA terminated due to lack of evidence submission.	No	NICE are unable to recommend this medicine for this indication
Head and neck cancer (squamous cell carcinoma) - cetuximab (TA172)	30/06/2009	Cetuximab – not recommended with platinum drugs for recurrent and/or metastatic squamous cell cancer of the head and neck.	Yes	
Multiple myeloma - lenalidomide (TA171)	30/06/2009	Lenalidomide – a recommended option with dexamethasone for multiple myeloma after failure of two previous treatments.	Yes	
Venous thromboembolism - rivaroxaban (TA170)	30/04/2009	Rivaroxaban – a recommended option for thromboembolism prophylaxis arising from elective total hip or knee replacement surgery.	Yes	